161 related articles for article (PubMed ID: 34835225)
1. Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8
Powell RM; Peeters MJW; Rahbech A; Aehnlich P; Seremet T; Thor Straten P
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835225
[TBL] [Abstract][Full Text] [Related]
2. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
3. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
4. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
6. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
7. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Rios-Doria J; Favata M; Lasky K; Feldman P; Lo Y; Yang G; Stevens C; Wen X; Sehra S; Katiyar K; Liu K; Wynn R; Harris JJ; Ye M; Spitz S; Wang X; He C; Li YL; Yao W; Covington M; Scherle P; Koblish H
Front Oncol; 2020; 10():598477. PubMed ID: 33425754
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
Zorn JA; Wang Q; Fujimura E; Barros T; Kuriyan J
PLoS One; 2015; 10(4):e0121177. PubMed ID: 25837374
[TBL] [Abstract][Full Text] [Related]
9. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
10. MerTK as a therapeutic target in glioblastoma.
Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
[TBL] [Abstract][Full Text] [Related]
11. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
12. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
13. MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Schlegel J; Sambade MJ; Sather S; Moschos SJ; Tan AC; Winges A; DeRyckere D; Carson CC; Trembath DG; Tentler JJ; Eckhardt SG; Kuan PF; Hamilton RL; Duncan LM; Miller CR; Nikolaishvili-Feinberg N; Midkiff BR; Liu J; Zhang W; Yang C; Wang X; Frye SV; Earp HS; Shields JM; Graham DK
J Clin Invest; 2013 May; 123(5):2257-67. PubMed ID: 23585477
[TBL] [Abstract][Full Text] [Related]
14. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
Yang X; Sexauer A; Levis M
Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
[TBL] [Abstract][Full Text] [Related]
16. Fms-Like Tyrosine Kinase 3-Ligand Contributes to the Development and Function of the Subpopulation of CD8α
Huang Y; Xu H; Miller T; Wen Y; Ildstad ST
Stem Cells; 2018 Oct; 36(10):1567-1577. PubMed ID: 30004616
[TBL] [Abstract][Full Text] [Related]
17. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Zhou F; Ge Z; Chen B
Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
[TBL] [Abstract][Full Text] [Related]
18. Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell-mediated T cell activation.
Wang R; Chen T; Wang C; Zhang Z; Wang XM; Li Q; Lee VWS; Wang YM; Zheng G; Alexander SI; Wang Y; Harris DCH; Cao Q
Nephrol Dial Transplant; 2019 Nov; 34(11):1853-1863. PubMed ID: 30590794
[TBL] [Abstract][Full Text] [Related]
19. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
20. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
